Open an account

Organogenesis Holdings

ORGO · NASDAQ

$1.02+$0.00 (+0.00%)TodayMarket closed ·
Prev close $1.02

About ORGO

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company is headquartered in Canton, Massachusetts and currently employs 854 full-time employees. The company went IPO on 2016-12-02. The company offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.

Employees
854
Headquarters
Canton, Massachusetts
Listed
Dec 2, 2016
Sector
Health Care
Industry
Biotechnology
Website
investors.organogenesis.com

ORGO key statistics

Market cap
131.25M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
691.37K
Volume
1.87M
Open price
$1.03
High today
$1.11
Low today
$1.00
52 Week high
$7.08
52 Week low
$0.9286

Organogenesis Holdings (ORGO) at a glance

Organogenesis Holdings (ORGO) last traded at $1.02, with a market cap of 131.25M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.00 and $1.11. The current price is 2.0% above the day's low and 7.7% below its high.

Volume so far is 1.87M shares, above the average of 691.37K shares a day.

Over the past year Organogenesis Holdings has ranged from $0.9286 to $7.08, and now sits 1% of the way up that range.

Organogenesis Holdings met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.73 per share against an estimate of -$0.357.

The average analyst price target is $2.04, 100.0% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 2 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 3 analystsAvg $2.04
Low
$2.02
Now
$1.02
High
$2.10

ORGO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 367.3% on average.

  1. Q3 FY24: reported $0.09 per share against an estimate of -$0.0153
  2. Q4 FY24: reported $0.06 per share against an estimate of -$0.0128
  3. Q1 FY25: reported -$0.10 per share against an estimate of -$0.0578
  4. Q2 FY25: reported -$0.10 per share against an estimate of -$0.0578
  5. Q3 FY25: reported $0.15 per share against an estimate of $0.0561
  6. Q4 FY25: reported $0.31 per share against an estimate of $0.2142
  7. Q1 FY26: reported -$0.41 per share against an estimate of -$0.3162
  8. Q2 FY26: reported -$0.73 per share against an estimate of -$0.357

ORGO news

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Press releasePRNewswire

    One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics

  • Press releaseGlobe Newswire

    Regenerative Medicine's Next Chapter: Inside the Race to Make the Body Rebuild Itself

  • Press releaseGlobe Newswire

    The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It

  • Press releasePRNewswire

    The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

Similar companies

Companies in the same industry as Organogenesis Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.